This article presents our experience regarding survival benefits in inoperable intermediate stage hepatocellular carcinoma (HCC) and advanced stage HCC treated with I-lipiodol. This is a retrospective study of intermediate stage HCC (Barcelona Clinic Liver Cancer [BCLC] stage B) not responding to prior treatment and/or advanced stage HCC (BCLC stage C) treated with I-lipiodol. I-lipiodol was injected into the hepatic artery through transfemoral route.
View Article and Find Full Text PDFBackground: The incidence of oropharyngeal carcinoma has been on the rise in recent decades. About 30% of patients who undergo definitive chemoradiation as the initial treatment present with residual/recurrent disease. In such a situation, surgical salvage either in the form of traditional open surgery or transoral robotic surgery (TORS) remains a viable treatment option.
View Article and Find Full Text PDFContext: Unresectable colorectal hepatic metastases can be treated with radioembolization.
Aims: The aim of this study is to analyze the response and survival benefits of transarterial radioembolization (TARE) with Iodine-131 (I) Lipiodol for hepatic metastases from gastrointestinal malignancies.
Settings And Design: Retrospective study of 20 patients with pathologically proven hepatic metastases from primary gastrointestinal malignancies referred for palliative therapy with TARE.
J Vasc Interv Radiol
February 1994
Purpose: The reactivity and patency of balloon-expandable Strecker stents were determined in the superior vena cava (SVC) and inferior vena cava (IVC) of rabbits.
Materials And Methods: One stent was placed in each of 24 rabbits; 15 were placed in the SVC and nine in the IVC. The duration of stent placement varied between 3 days and 15 months.